{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:50:49Z","timestamp":1787028649482,"version":"build-2736575974"},"reference-count":98,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Interstitial lung disease (ILD) encompasses a diverse group of parenchymal lung diseases characterized by varying degrees of inflammation and\/or fibrosis. Patients with ILD frequently require hospitalization, with many needing intensive care unit (ICU) admission, most often due to respiratory failure. The diagnosis and management of ILD in the ICU present unique challenges. Diagnosis primarily relies on chest CT imaging to identify fibrosis and inflammation. Acute exacerbations, whether in idiopathic pulmonary fibrosis (IPF) or non-IPF ILD, require careful evaluation of potential triggers and differential diagnoses. Bronchoalveolar lavage may provide valuable information, such as the identification of infections, but carries risks of complications. Biopsies, whether transbronchial or surgical, can also be informative but pose significant procedural risks. Corticosteroids are the cornerstone of treatment for acute exacerbations of IPF, with higher doses potentially benefiting non-IPF ILD. Additional immunosuppressive agents may be used in cases with evidence of inflammation. Oxygen supplementation, particularly with high-flow nasal cannula, is often employed to manage severe hypoxemia, while noninvasive ventilation can be useful for worsening hypoxemia and\/or hypercapnia. When mechanical ventilation is used, it is recommended to target low tidal volumes to minimize lung injury; high PEEP may be less effective and even associated with increased mortality. Prone positioning can improve oxygenation in severely hypoxemic patients. In addition to ventilatory strategies, careful fluid management and addressing concomitant pulmonary hypertension are essential components of care. Extracorporeal membrane oxygenation is a high-risk intervention reserved for the most severe cases. Lung transplantation may be considered for end-stage ILD patients in the ICU, with outcomes dependent on the urgency of transplantation and the patient\u2019s overall condition. Managing ILD in the ICU requires a multidisciplinary approach, and despite recent advances, mortality remains high, emphasizing the need for continued research and individualized treatment strategies.<\/jats:p>","DOI":"10.3390\/jcm13226657","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T06:27:39Z","timestamp":1730874459000},"page":"6657","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Management of Interstitial Lung Disease in the ICU: A Comprehensive Review"],"prefix":"10.3390","volume":"13","author":[{"given":"Zehra","family":"Dhanani","sequence":"first","affiliation":[{"name":"Thoracic Medicine and Surgery, Temple University Hospital, Philadelphia, PA 19140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8764-6538","authenticated-orcid":false,"given":"Rohit","family":"Gupta","sequence":"additional","affiliation":[{"name":"Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ccm.2021.03.002","article-title":"Diagnostic Classification of Interstitial Lung Disease in Clinical Practice","volume":"42","author":"Adegunsoye","year":"2021","journal-title":"Clin. Chest Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100020","DOI":"10.1016\/j.chstcc.2023.100020","article-title":"ICU Management of the Patient with Fibrotic Interstitial Lung Disease","volume":"1","author":"Krishnan","year":"2023","journal-title":"CHEST Crit. Care"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e001864","DOI":"10.1136\/bmjresp-2023-001864","article-title":"Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry","volume":"10","author":"Tsubouchi","year":"2023","journal-title":"BMJ Open Respir. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12931-021-01851-4","article-title":"IPF-PRO Registry Investigators Hospitalizations in patients with idiopathic pulmonary fibrosis","volume":"22","author":"Kim","year":"2021","journal-title":"Respir. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.5492\/wjccm.v11.i1.22","article-title":"Acute exacerbation of interstitial lung disease in the intensive care unit","volume":"11","author":"Charokopos","year":"2022","journal-title":"World J. Crit. Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report","volume":"194","author":"Collard","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Leuschner, G., and Behr, J. (2017). Acute Exacerbation in Interstitial Lung Disease. Front. Med., 4.","DOI":"10.3389\/fmed.2017.00176"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/resp.13682","article-title":"Acute exacerbations of fibrotic interstitial lung diseases","volume":"25","author":"Suzuki","year":"2020","journal-title":"Respirology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4103\/atm.atm_14_21","article-title":"Acute exacerbation in interstitial lung disease","volume":"16","author":"Alhamad","year":"2021","journal-title":"Ann. Thorac. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Xie, M., Zhu, C., and Ye, Y. (2023). Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis. BMC Pulm. Med., 23.","DOI":"10.1186\/s12890-023-02532-2"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/17476348.2018.1446831","article-title":"Treatment of acute exacerbations of interstitial lung disease","volume":"12","author":"Azadeh","year":"2018","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1177\/0885066613516579","article-title":"Connective Tissue Disease-Associated Interstitial Lung Disease: A Focused Review","volume":"30","author":"Solomon","year":"2015","journal-title":"J. Intensive Care Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2214\/ajr.184.2.01840613","article-title":"Isolated Diffuse Ground-Glass Opacity in Thoracic CT: Causes and Clinical Presentations","volume":"184","author":"Miller","year":"2005","journal-title":"Am. J. Roentgenol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Furini, F., Carnevale, A., Casoni, G.L., Guerrini, G., Cavagna, L., Govoni, M., and Scir\u00e9, C.A. (2019). The Role of the Multidisciplinary Evaluation of Interstitial Lung Diseases: Systematic Literature Review of the Current Evidence and Future Perspectives. Front. Med., 6.","DOI":"10.3389\/fmed.2019.00246"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1164\/rccm.200703-463PP","article-title":"Acute Exacerbations of Idiopathic Pulmonary Fibrosis","volume":"176","author":"Collard","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.chest.2015.12.026","article-title":"Patients with Fibrotic Interstitial Lung Disease Hospitalized for Acute Respiratory Worsening","volume":"149","author":"Moua","year":"2016","journal-title":"Chest"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1164\/rccm.202004-1138LE","article-title":"BAL Is Safe and Well Tolerated in Individuals with Idiopathic Pulmonary Fibrosis: An Analysis of the PROFILE Study","volume":"203","author":"Molyneaux","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.21037\/jtd-19-3659","article-title":"Clinical usefulness of bronchoalveolar lavage in patients with interstitial lung diseases: A pilot study","volume":"12","author":"Chang","year":"2020","journal-title":"J. Thorac. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/resp.12909","article-title":"Bronchoscopy assessment of acute respiratory failure in interstitial lung disease","volume":"22","author":"Arcadu","year":"2017","journal-title":"Respirology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-0043-1764375","article-title":"Pneumocystis jiroveci Pneumonia: A Review of Management in Human Immunodeficiency Virus (HIV) and Non-HIV Immunocompromised Patients","volume":"13","author":"Ibrahim","year":"2023","journal-title":"Avicenna J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Schnabel, R.M., van der Velden, K., Osinski, A., Rohde, G., Roekaerts, P.M.H.J., and Bergmans, D.C.J.J. (2015). Clinical course and complications following diagnostic bronchoalveolar lavage in critically ill mechanically ventilated patients. BMC Pulm. Med., 15.","DOI":"10.1186\/s12890-015-0104-1"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ghiani, A., and Neurohr, C. (2021). Diagnostic yield, safety, and impact of transbronchial lung biopsy in mechanically ventilated, critically ill patients: A retrospective study. BMC Pulm. Med., 21.","DOI":"10.1186\/s12890-020-01357-7"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/LBR.0000000000000767","article-title":"Transbronchial Forceps Biopsy in the Intensive Care Unit: A Systematic Review and Meta-analysis","volume":"28","author":"Helgeson","year":"2021","journal-title":"J. Bronchol. Interv. Pulmonol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/imj.13222","article-title":"Utility of surgical lung biopsy in critically ill patients with diffuse pulmonary infiltrates: A retrospective review","volume":"46","author":"Donaldson","year":"2016","journal-title":"Intern. Med. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/8715024","article-title":"The Role of Open Lung Biopsy in Critically Ill Patients with Hypoxic Respiratory Failure: A Retrospective Cohort Study","volume":"2016","author":"Almotairi","year":"2016","journal-title":"Can. Respir. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S2213-2600(21)00354-4","article-title":"Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"10","author":"Naccache","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2169\/internalmedicine.50.4327","article-title":"Tacrolimus and Steroid Treatment for Acute Exacerbation of Idiopathic Pulmonary Fibrosis","volume":"50","author":"Horita","year":"2011","journal-title":"Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2169\/internalmedicine.49.2359","article-title":"Cyclosporin A in the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis","volume":"49","author":"Sakamoto","year":"2010","journal-title":"Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Donahoe, M., Valentine, V.G., Chien, N., Gibson, K.F., Raval, J.S., Saul, M., Xue, J., Zhang, Y., and Duncan, S.R. (2015). Correction: Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0133684"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Jang, H.J., Yong, S.H., Leem, A.Y., Lee, S.H., Kim, S.Y., Lee, S.H., Kim, E.Y., Chung, K.S., Jung, J.Y., and Kang, Y.A. (2021). Corticosteroid responsiveness in patients with acute exacerbation of interstitial lung disease admitted to the emergency department. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-85539-1"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus Placebo in Scleroderma Lung Disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_34","first-page":"157","article-title":"Cyclophosphamide pulse therapy as treatment for severe interstitial lung diseases","volume":"36","author":"Schulze","year":"2019","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10067-005-1157-y","article-title":"A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis","volume":"25","author":"Nadashkevich","year":"2006","journal-title":"Clin. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2202071","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): A double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): A double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1183\/09031936.00163911","article-title":"Severe interstitial lung disease in connective tissue disease: Rituximab as rescue therapy","volume":"40","author":"Keir","year":"2012","journal-title":"Eur. Respir. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): A phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","article-title":"Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease","volume":"50","author":"Castellvi","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjd.14882","article-title":"Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis","volume":"176","author":"Matsushita","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-020-05530-5","article-title":"Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy","volume":"40","author":"Ge","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment","volume":"59","author":"Shirakashi","year":"2020","journal-title":"Rheumatology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1093\/rheumatology\/keab928","article-title":"Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"61","author":"Wang","year":"2022","journal-title":"Rheumatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13075-021-02435-9","article-title":"Risk factors for mortality of diffuse alveolar hemorrhage in systemic lupus erythematosus: A systematic review and meta-analysis","volume":"23","author":"Jiang","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.chest.2023.01.031","article-title":"Diagnosis and Management of Myositis-Associated Lung Disease","volume":"163","author":"Hallowell","year":"2023","journal-title":"Chest"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Park, J.A. (2021). Treatment of Diffuse Alveolar Hemorrhage: Controlling Inflammation and Obtaining Rapid and Effective Hemostasis. Int. J. Mol. Sci., 22.","DOI":"10.37247\/PAMOL2ED.2.2021.17"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/SMJ.0b013e3182126d3b","article-title":"Diffuse Alveolar Hemorrhage","volume":"104","author":"Newsome","year":"2011","journal-title":"South. Med. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1053\/j.ajkd.2003.08.015","article-title":"Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis","volume":"42","author":"Klemmer","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000489890","article-title":"Efficacy and Tolerability of High-Flow Nasal Cannula Oxygen Therapy for Hypoxemic Respiratory Failure in Patients with Interstitial Lung Disease with Do-Not-Intubate Orders: A Retrospective Single-Center Study","volume":"96","author":"Koyauchi","year":"2018","journal-title":"Respiration"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1001\/jamainternmed.2014.5430","article-title":"Outcomes Associated with Invasive and Noninvasive Ventilation Among Patients Hospitalized With Exacerbations of Chronic Obstructive Pulmonary Disease","volume":"174","author":"Lindenauer","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"170062","DOI":"10.1183\/16000617.0062-2017","article-title":"Physiology of the lung in idiopathic pulmonary fibrosis","volume":"27","author":"Plantier","year":"2018","journal-title":"Eur. Respir. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"232","DOI":"10.29390\/001c.89284","article-title":"Effect of Noninvasive Respiratory Support on Interstitial Lung Disease with Acute Respiratory Failure: A Systematic Review and Meta-Analysis","volume":"59","author":"Sanguanwong","year":"2023","journal-title":"Can. J. Respir. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000225932","article-title":"Mechanical Ventilation in Patients with End-Stage Idiopathic Pulmonary Fibrosis","volume":"79","author":"Mollica","year":"2010","journal-title":"Respiration"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/CPM.0000000000000312","article-title":"Noninvasive Oxygenation Strategies for Acute Exacerbation of Interstitial Lung Disease: A Retrospective Single-center Study and a Review of the Literature","volume":"26","author":"Imai","year":"2019","journal-title":"Clin. Pulm. Med."},{"key":"ref_58","first-page":"301","article-title":"High-flow nasal cannula therapy for acute respiratory failure in patients with interstitial pneumonia: A retrospective observational study","volume":"82","author":"Omote","year":"2020","journal-title":"Nagoya J. Med. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4103\/ejcdt.ejcdt_33_18","article-title":"High-flow nasal oxygen therapy versus noninvasive ventilation in chronic interstitial lung disease patients with acute respiratory failure","volume":"67","author":"Shebl","year":"2018","journal-title":"Egypt. J. Chest Dis. Tuberc."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/CCM.0000000000004366","article-title":"Mechanical Ventilation and Predictors of In-Hospital Mortality in Fibrotic Interstitial Lung Disease with Acute Respiratory Failure: A Cohort Analysis Through the Paradigm of Acute Respiratory Distress Syndrome","volume":"48","author":"Martin","year":"2020","journal-title":"Crit. Care Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.resinv.2023.01.008","article-title":"Mechanical ventilation for acute exacerbation of fibrosing interstitial lung diseases","volume":"61","author":"Matsunashi","year":"2023","journal-title":"Respir. Investig."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13613-020-0632-6","article-title":"Ventilatory support and mechanical properties of the fibrotic lung acting as a \u201csquishy ball\u201d","volume":"10","author":"Marchioni","year":"2020","journal-title":"Ann. Intensive Care"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"The Acute Respiratory Distress Syndrome Network (2000). Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome. N. Engl. J. Med., 342, 1301\u20131308.","DOI":"10.1056\/NEJM200005043421801"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1378\/chest.07-2615","article-title":"Mechanical Ventilation in Interstitial Lung Disease","volume":"133","author":"Baydur","year":"2008","journal-title":"Chest"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/crj.13223","article-title":"Mechanical ventilation for acute respiratory failure due to idiopathic pulmonary fibrosis versus connective tissue disease-associated interstitial lung disease: Effectiveness and risk factors for death","volume":"14","author":"Luo","year":"2020","journal-title":"Clin. Respir. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1378\/chest.07-1481","article-title":"Ventilator Settings and Outcome of Respiratory Failure in Chronic Interstitial Lung Disease","volume":"133","author":"Yilmaz","year":"2008","journal-title":"Chest"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa1214103","article-title":"Prone Positioning in Severe Acute Respiratory Distress Syndrome","volume":"368","author":"Reignier","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/crj.12665","article-title":"Prone position ventilation support for acute exacerbation of interstitial lung disease?","volume":"12","author":"Xu","year":"2018","journal-title":"Clin. Respir. J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2169\/internalmedicine.50.4508","article-title":"Clinical and Radiological Features of Acute-Onset Diffuse Interstitial Lung Diseases in Patients with Rheumatoid Arthritis Receiving Treatment with Biological Agents: Importance of Pneumocystis Pneumonia in Japan Revealed by a Multicenter Study","volume":"50","author":"Kameda","year":"2011","journal-title":"Intern. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1183\/09059180.00001011","article-title":"Pulmonary aspergillosis: A clinical review","volume":"20","author":"Kousha","year":"2011","journal-title":"Eur. Respir. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis\u2013Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12931-019-1161-4","article-title":"Antifibrotic therapy for idiopathic pulmonary fibrosis: Time to treat","volume":"20","author":"Maher","year":"2019","journal-title":"Respir. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.chest.2021.06.049","article-title":"Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis","volume":"160","author":"Petnak","year":"2021","journal-title":"Chest"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1901760","DOI":"10.1183\/13993003.01760-2019","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: International survey and call for harmonisation","volume":"55","author":"Kreuter","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/ehjacc\/zuad157","article-title":"Diagnosis and treatment of right ventricular failure secondary to acutely increased right ventricular afterload (acute cor pulmonale): A clinical consensus statement of the Association for Acute CardioVascular Care of the European Society of Cardiology","volume":"13","author":"Arrigo","year":"2024","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1183\/09031936.00171307","article-title":"Pulmonary hypertension in interstitial lung disease","volume":"31","author":"Behr","year":"2008","journal-title":"Eur. Respir. J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ccm.2013.08.004","article-title":"Pulmonary Hypertension due to Lung Disease and\/or Hypoxia","volume":"34","author":"Nathan","year":"2013","journal-title":"Clin. Chest Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.rmed.2006.02.004","article-title":"The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis","volume":"100","author":"Lettieri","year":"2006","journal-title":"Respir. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1183\/09059180.00002713","article-title":"Pulmonary hypertension in chronic interstitial lung diseases","volume":"22","author":"Caminati","year":"2013","journal-title":"Eur. Respir. Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2018.04.015","article-title":"Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry","volume":"139","author":"Baughman","year":"2018","journal-title":"Respir. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1378\/chest.118.4.1077","article-title":"Hemodynamic Effects of Epoprostenol in Patients with Systemic Sclerosis and Pulmonary Hypertension","volume":"118","author":"Strange","year":"2000","journal-title":"Chest"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/ajrccm.160.2.9810008","article-title":"Inhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis","volume":"160","author":"Olschewski","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1164\/rccm.202212-2342CI","article-title":"Progress in the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease","volume":"208","author":"Nathan","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.21037\/jtd-20-1635","article-title":"Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction","volume":"13","author":"Hinkamp","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jtcvs.2012.12.022","article-title":"Extracorporeal membrane oxygenation as a bridge to pulmonary transplantation","volume":"145","author":"Hoopes","year":"2013","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1164\/rccm.201508-1701OC","article-title":"Outcome of Patients with Interstitial Lung Disease Treated with Extracorporeal Membrane Oxygenation for Acute Respiratory Failure","volume":"193","author":"Trudzinski","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12931-024-02968-y","article-title":"Extracorporeal membrane oxygenation as a bridge to lung transplantation: 5-year outcomes and bridge to decision in a large, older cohort","volume":"25","author":"Daar","year":"2024","journal-title":"Respir. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.healun.2021.07.005","article-title":"Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation","volume":"40","author":"Leard","year":"2021","journal-title":"J. Heart Lung Transplant."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.chest.2018.06.027","article-title":"Effect of Acute Exacerbation of Idiopathic Pulmonary Fibrosis on Lung Transplantation Outcome","volume":"154","author":"Dotan","year":"2018","journal-title":"Chest"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jtcvs.2020.02.140","article-title":"Urgently listed lung transplant patients have outcomes similar to those of electively listed patients","volume":"161","author":"Tang","year":"2021","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.21037\/jtd.2018.06.141","article-title":"Lung transplantation: Indications and contraindications","volume":"10","author":"Weill","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/rheumatology\/keq233","article-title":"The impact of rheumatological evaluation in the management of patients with interstitial lung disease","volume":"50","author":"Castelino","year":"2011","journal-title":"Rheumatology"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Lindell, K.O., and Danoff, S.K. (2021). Palliative Care in Interstitial Lung Disease. Palliative Care in Lung Disease, Springer International Publishing. Respiratory Medicine.","DOI":"10.1007\/978-3-030-81788-6"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"525","DOI":"10.4187\/respcare.01734","article-title":"Why Do Patients with Interstitial Lung Diseases Fail in the ICU? A 2-Center Cohort Study","volume":"58","author":"Tatar","year":"2013","journal-title":"Respir. Care"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"180061","DOI":"10.1183\/16000617.0061-2018","article-title":"Risk factors for mortality and mortality rates in interstitial lung disease patients in the intensive care unit","volume":"27","author":"Huapaya","year":"2018","journal-title":"Eur. Respir. Rev."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"175346662092695","DOI":"10.1177\/1753466620926956","article-title":"Outcome and prognostic factors of interstitial lung disease patients with acute respiratory failure in the intensive care unit","volume":"14","author":"Lain","year":"2020","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Drakopanagiotakis, F., Markart, P., and Steiropoulos, P. (2023). Acute Exacerbations of Interstitial Lung Diseases: Focus on Biomarkers. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241210196"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/22\/6657\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:27:11Z","timestamp":1760113631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/22\/6657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":98,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["jcm13226657"],"URL":"https:\/\/doi.org\/10.3390\/jcm13226657","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]}}}